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Glutathione S-transferase and Microsomal Epoxide Hydrolase Gene 
Polymorphisms and Risk of Chronic Obstructive Pulmonary Disease in 
Slovak Population
Aim To determine the risk of chronic obstructive pulmonary disease 
(COPD) associated with polymorphisms in the glutathione S-transfer-
ase (GST) M1, GST T1, and microsomal epoxide hydrolase (EPHX1) 
genes in a cohort of Slovak population.
Methods Two hundred and seventeen patients with the diagnosis of 
COPD and 160 control subjects were enrolled in the study. Blood 
samples were collected from all subjects and the DNA from peripheral 
blood lymphocytes was used for subsequent genotyping assays, using 
polymerase chain reaction and restriction fragment-length polymor-
phism methods.
Results In an unadjusted model, an increased risk for COPD was ob-
served in subjects with EPHX1 His113-His113 genotype (odds ratio 
[OR], 2.32; 95% confidence interval [CI], 1.20-4.69; P = 0.008), com-
pared with the carriers of the Tyr113 allele. However, after the adjust-
ments for age, sex, and smoking status, the risk was not significant (ad-
justed OR, 1.79; 95% CI, 0.91-3.53; P = 0.093). In a combined analysis 
of gene polymorphisms, the genotype combination EPHX1 His113-
His113/GSTM1 null significantly increased the risk of COPD in both, 
unadjusted (OR, 5.08; 95% CI, 1.70-20.43; P = 0.001) and adjusted 
model (OR, 4.87; 95% CI, 1.57-15.13; P = 0.006).
Conclusion Although none of the tested gene polymorphisms was sig-
nificantly related to an increased risk of COPD alone, our results sug-
gest that the homozygous exon 3 mutant variant of EPHX1 gene in the 
combination with GSTM1 null genotype is a significant predictor of 
increased susceptibility to COPD in the Slovak population. The find-
ings of the present study emphasize the importance of detoxifying and 
antioxidant pathways in the pathogenesis of COPD.
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Chronic obstructive pulmonary disease 
(COPD) represents a major public health 
care problem worldwide due to its increas-
ing prevalence, morbidity, and mortality (1). 
Generally, COPD is characterized by pro-
gressive and only partially reversible airflow 
limitation (2). Although cigarette smoking 
is the most important risk factor for COPD, 
only 20%-30% of chronic smokers develop 
severe impairment of lung function associat-
ed with COPD (3). Besides smoking, other 
environmental and genetic factors and gene-
environment interactions influence the de-
velopment of COPD (4).
Severe α-1-antitrypsin deficiency is a well 
established genetic risk factor for COPD that 
has provided a basis for the protease-antipro-
tease hypothesis in the pathogenesis of COPD 
(5,6). Other candidate genes that might play 
a role in the development of COPD are in-
volved in endogenous protease/antiprotease 
imbalance, inflammatory processes, metabo-
lism of mutagens and carcinogens in tobac-
co smoke, and in mucocilliary clearance (7). 
Interindividual differences in the polymor-
phisms of enzymes metabolizing the xenobiot-
ic substances and free radicals contained in the 
cigarette smoke may play a role in the individ-
ual susceptibility to the decrease in lung func-
tions in smokers (8).
Microsomal epoxide hydrolase (EPHX1) 
is generally considered to be a protective en-
zyme involved in the defense from oxidative 
damage (9,10). Two common polymorphic 
sites in the EPHX1 gene that influence the 
enzyme activity can be detected (11). An exon 
3 thymine-to-cytosine mutation changes Tyr 
residue 113 to His, thus reducing the enzyme 
activity by about 50%. The second mutation, 
an adenine-to-guanine transition in exon 4 
of the gene, changes His residue 139 to Arg 
and results in the production of EPHX1 with 
the activity increased by about 25% (11). The 
combination of these polymorphisms leads to 
a formation of several functional phenotypes 
of EPHX1. The slow metabolizing type of 
EPHX1 was associated with emphysema and 
COPD (9). In another study, an association 
of slow metabolizing EPHX1 phenotype with 
an accelerated deterioration of lung function 
in smokers was observed (12). In addition, 
several studies conducted in different popu-
lations have suggested that the EPHX1 geno-
type may influence individual susceptibility to 
COPD (9,13-15). Nevertheless, other inves-
tigators failed to confirm an association be-
tween the EPHX1 gene polymorphisms and 
COPD (16-18).
Glutathione S-transferases (GST) play a 
role in the detoxification of carcinogenic com-
pounds contained in cigarette smoke and in 
the antioxidant protection (19,20). Recently, 
the GSTM1 and the GSTT1 gene polymor-
phisms have been excessively studied with re-
spect to their potential contribution to the 
risk of COPD (8,17,21,22). The deficiency in 
the activity of GSTM1 and GSTT1 enzymes 
is caused by the inherited homozygous ab-
sence of the GSTM1 or GSTT1 gene, respec-
tively (ie, GSTM1 null or GSTT1 null geno-
type). Previously, the homozygous GSTM1 
null genotype has been associated with lung 
cancer (23), emphysema (21), and reductions 
in the lung function in Caucasian smokers 
with non-small-cell lung cancer (22). Howev-
er, another study conducted in Koreans found 
no differences in the frequencies of polymor-
phic genotypes of GSTM1 and GSTT1 genes 
between patients with COPD and healthy 
smokers (17).
Since current data on the potential associ-
ations between an increased COPD risk and 
genes encoding the enzymes metabolizing xe-
nobiotic substances are inconsistent, the aim 
of our study was to analyze the relation be-
tween COPD and gene polymorphisms of 
EPHX1, GSTM1, and GSTT1 genes in a sam-
ple of Slovak population.




Patients with the diagnosis of COPD stage 
I to IV according to the American Thoracic 
Society/European Respiratory Society guide-
lines (1,2) referred to an outpatient respira-
tory clinic in a tertiary university hospital in 
Slovakia were consecutively recruited in the 
study in the period 2004-2007. The presence 
of fixed airflow obstruction was confirmed 
by spirometry in all patients with postbron-
chodilator Tiffeneau ratio <0.7 and negative 
bronchodilator reversibility test results (1,2). 
Exclusion criteria were respiratory disorders 
other than COPD, such as interstitial lung 
disease, bronchiolitis obliterans, diffuse bron-
chiectasis, lung cancer, tuberculosis, previous 
medical records of bronchial asthma, thoracic 
surgery in the past, and/or recent pulmonary 
infiltrate or pleural effusion on chest x-ray. Pa-
tients with pulmonary embolism, overt heart 
failure, malignancy, systemic autoimmune dis-
orders, infectious diseases, recent surgery, se-
vere endocrine, hepatic or renal diseases, and 
patients unable to perform spirometry to con-
firm the diagnosis were also excluded. Healthy 
age-matched subjects without previous medi-
cal history of respiratory disorders and with-
out any present respiratory symptoms, seen by 
their general practitioner for a regular check-
up, were recruited consecutively as controls. 
All COPD patients and controls were indi-
viduals from the general population of Eastern 
Slovakia. The study was approved by the insti-
tutional ethics committee and all subjects gave 
their written informed consent.
Pulmonary function tests
In patients, pulmonary function tests were 
performed with a bodyplethysmograph (Jae-
ger, Höchberg, Germany) 20 minutes before 
and after 400 μg dose of inhaled salbutamol 
(Ventolin; GlaxoSmithKline, Greenford, Mid-
dlesex, UK). Short-acting inhaled drugs were 
not used 6 hours before the testing, and long-
acting bronchodilator therapy was stopped for 
12 hours before the test. Bodyplethysmograph 
was calibrated before use. All pulmonary func-
tion testing was performed according to the 
European Respiratory Society standards, with 
the patients in the sitting position and the 
same technician performing the test in order 
to ensure the consistency (24). Three techni-
cally acceptable measurements were performed 
in each patient before and after salbutamol in-
halation; the highest value was included in the 
analyses.
Genotyping assays
Blood (4 mL) for genotyping was drawn into 
an EDTA-tube by routine venipuncture and 
stored at -20°C until DNA extraction was car-
ried out. Genomic DNA was isolated from 
the separated peripheral blood lymphocytes 
using Wizard Genomic DNA Purification 
Kit (#A1125, Promega Corp., Madison, WI, 
USA).
Two separate polymerase chain reactions 
(PCR) were used to detect two mutations in 
the EPHX1 gene (9). The primer pairs EPO1 
(5′-GATCGATAAGTTCCGTTTCACC-
3′) and EPo2 (5′-ATCCTTAGTCTT-
GAAGTGAGGAT-3′) were used for exon 3 
variants. The primer pairs EPO3 (5′-ACATC-
CACTTCATCCACGT-3′) and EPO4 (5′-
ATGCCTCTGAGAAGCCAT-3′) were 
used to test mutation in exon 4. PCR was 
carried out on MJ Research thermal cycler 
(Minicycler PTC-150, MJ Research Inc., Wa-
tertown, MA, USA). For exon 3, the PCR 
conditions were as follows: after 5 minutes of 
pretreatment at 94°C, the reaction mixture 
was subjected to 47 cycles at 94°C for 1 min-
ute, at 46°C for 70 seconds, and at 72°C for 70 
seconds; for exon 4, the initial pretreatment 
at 94°C for 5 minutes was followed by 38 cy-
cles at 94°C for 1 minute, at 56°C for 1 min-
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ute, and at 72°C for 1 minute. Final extension 
was carried out at 72°C for 10 minutes. The 
resulting DNA fragments were digested with 
EcoRV (exon 3) and RsaI (exon 4) (37°C, 
overnight). Negative controls were included in 
every PCR run. The fragments were separated 
on 3% agarose gel after enzyme digestion. The 
gels were stained with ethidium bromide and 
transilluminated with the UV light (Figure 1).
The plus/minus (null/non-null) poly-
morphism of the GSTM1 and GSTT1 genes 
were determined according to the PCR-based 
method of Arand et al (25), where the simul-
taneous amplification of GSTM1 and GSTT1 
genomic fragments in the same reaction was 
performed. The resulting PCR fragments were 
separated by electrophoresis on 3% agarose 
gel, followed by ethidium bromide staining 
and directly visualized by UV detection. The 
primer pairs for this multiplex PCR were the 
following: 5′-GAACTCCCTGAAAAGC-
TAAAGC-3′ and 5′-GTTGGGCT-
CAAATATACGGTGG-3′ for GSTM1; 5′-
TTCCTTACTGGTCCTCACATCTC-3′ 
and 5′-TCACCGGATCATGGCCAGCA-
3′ for GSTT1; and 5′-GCCCTCTGCTA-
ACAAGTCCTAC-3′ and 5′-GCCCTA-
AAAAGAAAATCGCCAATC-3′ for 
albumin. Multiplex PCR analysis was carried 
out in MJ Research thermal cycler under the 
following conditions: initial pretreatment at 
95°C for 2 minutes, followed by 30 cycles at 
94°C for 1 minute, at 64°C for 1 minute, and 
at 72°C for 1 minute. Final extension was car-
ried out at 72°C for 5 minutes. The involve-
Figure 1. Polymerase chain reaction analysis of two polymorphic loci 
in epoxide hydrolase 1 (EPHX1) gene. Lanes 1-3 – EPHX1 exon 3 
polymorphism: 1. His/His; 2. Tyr/His; 3. Tyr/Tyr. Lanes 4-6 – EPHX1 
exon 4 polymorphism: 4. His/Arg; 5. Arg/Arg; 6. His/His. Lane 7 – 100 
bp ladder (#N3231S, New England Biolabs, Ipswitch, USA).
Figure 2. Multiplex polymerase chain reaction analysis of glutathione 
S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) 
polymorphisms. Lane 1 – GSTM1 non-null/GSTT1 non-null. Lane 2 
– GSTM1 non-null/GSTT1 null. Lane 3 – GSTM1 null/GSTT1 non-null. 
Lane 4 – GSTM1 null/GSTT1 null genotype. Lane 5 – 100 bp ladder 
(#N3231S, New England Biolabs, Ipswitch, USA).
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ment of GSTM1 deficiency was concluded 
from the absence of the specific 215 base pair 
(bp) fragment and GSTT1 deficiency from 
the absence of 480 bp fragment. Albumin gene 
fragment used as internal positive control re-
sulted in constant 350 bp band in all samples 
(Figure 2). Subjects with heterozygous (+/0) 
and non-null homozygous (+/+) GSTM1 or 
GSTT1 genotypes were pooled together and 
formed the non-null genotype group, in agree-
ment with previous studies (22), indicating 
that individuals with GSTM1 heterozygous 
and non-null homozygous genotypes have 
similar GST expression level in the liver (26). 
To test the consistency of the genotyping and 
to detect possible misgenotyping, 20 random 
samples from patients with COPD and 20 
samples from the control group were retested. 
All the results of retested samples matched the 
previous ones.
Statistical analysis
Demographic data and spirometric parameters 
are presented as means ± standard deviation. 
Mann-Whitney U-tests were used to compare 
the means and χ2 tests to compare the propor-
tions of categorical variables in cases and con-
trols. The distributions of genotypes for each 
polymorphic site in the EPHX1 gene were 
tested to match the Hardy-Weinberg heredity 
equilibrium by χ2 tests.
Crude odds ratios (OR) and 95% con-
fidence intervals (CI) were calculated using 
Gart’s method (27) to examine the association 
between the GSTM1, GSTT1, and EPHX1 
genotypes, and the risk of COPD. The reces-
sive model was used, in which homozygous 
mutant genotype was compared with the re-
maining genotypes within the tested gene. In 
addition, logistic regression was used to de-
termine the odds ratios adjusted for potential 
confounding factors (age, sex, and smoking 
status). All tests were performed using Statis-
tical Package for the Social Sciences, version 
14.0 (SPSS Inc., Chicago, IL, USA). P<0.05 
was considered significant.
Results
A total of 377 Caucasians (217 patients with 
COPD and 160 control subjects) were en-
rolled in the study. No differences were ob-
served between control subjects and COPD 
patients in mean age (63 ± 18 vs 67 ± 11 
years; P = 0.09). The proportion of women 
was higher (46% vs 25%; P<0.001) and the 
proportion of smokers was lower (39% vs 
78%; P<0.001) in control group than in pa-
tients with COPD. Mean smoking histo-
ry in controls was 5 ± 18 pack-years. Patients 
with COPD had a 27 ± 25 pack-years his-
tory of smoking; their pulmonary function 
tests showed predicted mean post-broncho-
dilator forced expiratory volume in one sec-
ond (FEV1) of 49 ± 21%, and predicted mean 
forced vital capacity (FVC) of 70 ± 22%, with 
mean FEV1/FVC ratio 57 ± 15%.
Genotype distributions of GSTM1, 
GSTT1, and EPHX1 gene polymorphisms in 
the studied population are reported in Table 
1. Genotype distributions for exon 3 and exon 
4 polymorphisms in the EPHX1 gene were in 
the Hardy-Weinberg equilibrium (P = 0.994 
and P = 0.696, respectively).
In an unadjusted model, the EPHX1 
His113-His113 genotype at exon 3 was associ-
ated with an increased COPD risk (OR, 2.32; 
95% CI, 1.20-4.69; P = 0.008). However, this 
association did not remain significant after 
the adjustments for age, sex, and smoking sta-
tus (OR, 1.79; 95% CI, 0.91-3.53; P = 0.093) 
(Table 1). In contrast, no association with 
COPD risk, expressed both as crude and ad-
justed odds ratios, was observed in exon 4 co-
don 139 polymorphic site of the EPHX1 gene. 
Furthermore, no significant associations were 
observed between the GSTM1 or GSTT1 gen-
otypes and the risk of COPD (Table 1).
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To assess whether the combinations of the 
EPHX1, GSTM1, and GSTT1 genotype poly-
morphisms are associated with an increased 
risk for the development of COPD, the 
GSTM1, GSTT1, and EPHX1 gene polymor-
phisms were analyzed in combinations. Table 
2 shows the distributions of combined geno-
types of GSTM1, GSTT1, and EPHX1 genes 
in cases and controls. In crude combined anal-
ysis of gene polymorphisms for the EPHX1, 
GSTM1, and GSTT1 genes, the combined 
EPHX1 His113-His113/GSTM1 null geno-
type was associated with significantly increased 
risk of COPD (OR, 5.08; 95% CI, 1.70-20.43; 
P = 0.001). After adjustments for age, sex, and 
smoking status, the relationship between the 
combined EPHX1 His113-His113/GSTM1 
null genotype and the increased risk for 
COPD remained significant (OR, 4.87; 95% 
CI, 1.57-15.13; P = 0.006).
Discussion
The combination of His113-His113 EPHX1 
polymorphism at codon 113 with the 
GSTM1 null/non-null gene polymorphism 
significantly increased the risk of COPD in 
a sample of Slovak population, whereas none 
of the studied polymorphisms alone predict-
ed the risk.
Table 1. Genotype distribution of glutathione S-transferase M1 (GSTM1), glutathione S-transferase T1 (GSTT1), and epoxide hydrolase 
1 (EPHX1) in patients with chronic obstructive pulmonary disease and healthy controls in a sample of Slovak population*
No. (%) of OR (95% CI) for OR adjusted (95% CI) for
Genotype COPD cases controls homozygous mutation P homozygous mutation† P
GSTM1:
 non-null genotype  88 (40.6)  75 (46.9)
 null genotype 129 (59.4)  85 (53.1) 1.29 (0.84-1.99) 0.221 1.34 (0.85-2.12) 0.208
GSTT1:
 non-null genotype 178 (82.0) 129 (80.6)
 null genotype  39 (18.0)  31 (19.4) 0.91 (0.52-1.60) 0.729 0.91 (0.51-1.64) 0.766
EPHX1 exon 3 codon 113:
 Tyr/Tyr 105 (48.4)  78 (48.8)
 Tyr/His  70 (32.3)  67 (41.9)
 His/His  42 (19.3)  15 (9.3) 2.32 (1.20-4.69) 0.008 1.79 (0.91-3.53) 0.093
EPHX1 exon 4 codon 139:
 His/His 140 (64.5)  91 (56.9)
 His/Arg  69 (31.8)  63 (39.4)
 Arg/Arg   8 (3.7)   6 (3.7) 0.98 (0.29-3.51) 0.974 0.61 (0.20-1.90) 0.393
*Abbreviations: COPD – chronic obstructive pulmonary disease; OR – odds ratio; CI – confidence interval.
†Adjusted for potential confounding factors (age, sex, and smoking status).
Table 2. Distribution of combined genotypes of glutathione S-transferase M1 (GSTM1), glutathione S-transferase T1 (GSTT1), and 
epoxide hydrolase 1 (EPHX1) genes in patients with chronic obstructive pulmonary disease and healthy controls in a sample of Slovak 
population
No. of patients/controls
EPHX1 exon4 GSTM1 GSTT1










 Tyr/Tyr  68/44 34/34 3/0 40/33  65/45 84/61 21/17
 Tyr/His  47/38 21/25 2/4 31/31  39/36 58/53 12/14
 His/His  25/9 14/4 3/2 17/11  25/4 36/15  6/0
GSTT1:
 Non-null genotype 118/73 53/51 7/5 75/64 103/65
 Null genotype  22/18 16/12 1/1 13/11  26/20
GSTM1:
 Non-null genotype  55/44 27/27 6/4
 Null genotype  85/47 42/36 2/2
Combined GSTM1 null and EPHX1
 exon 3 His/His
5.08 (1.70-20.43)* 4.87 (1.57-15.13)†
*Odds ratio (95% confidence interval); P = 0.001.
†Adjusted odds ratio (95% confidence interval); P = 0.006.
Croat Med J 2008;49:182-191
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The only well-established genetic cause of 
COPD, the α-1-antitrypsin deficiency, is rare 
(6). A number of studies have been performed 
to find other susceptibility genes of COPD, 
and a variety of approaches have been used to 
identify them. Familial aggregation study on 
5003 subjects participating in the Framing-
ham Study suggested polygenic inheritance of 
obstructive ventilatory impairment, with the 
genetic component consisting of several genes 
of a small effect each rather than of a single 
major gene (28). In a genome-wide scan of 
pulmonary function measures in the Nation-
al Heart, Lung, and Blood Institute Family 
Heart Study, FEV1 and FVC were suggestively 
linked to regions on the chromosome 18 (29). 
In addition, many studies were performed to 
search for potential associations between a giv-
en gene polymorphism and susceptibility to 
COPD (7,30-32). Up to now, more than 25 
different candidate genes have been investigat-
ed for their potential role in lung function im-
pairment in smokers (7,30-32).
The evidence of a linkage between the can-
didate genes and COPD and its associated 
phenotypes is seldom definitive and is often 
conflicting (33). The development and pro-
gression of COPD involves multiple genes, 
gene-gene, and gene-environment interactions 
(4). In general, although association studies 
have successfully identified various significant 
genetic associations to the reduction in lung 
function in smokers (7,9,12-15,21,22,31), the 
inconsistency and lack of replication has been 
a major flaw in these studies. In addition, in 
some studies the distribution of genotypes 
deviated from Hardy-Weinberg equilibri-
um (9,14,17). Moreover, COPD is a hetero-
geneous disease, and its definition has been 
changing over the last decade (1,2). As a result, 
genetic association studies in patients with 
COPD use different phenotype definition of 
the disease. In our study, the current defini-
tion of COPD according to GOLD guidelines 
(2) was used, and the cohort of subjects under 
investigation was ethnically well defined.
One of the possible approaches to under-
standing the influence of genetic factors on 
COPD, as well as their mutual interactions, is 
to assess the combined genotypes (34) in an ef-
fort to explain gene-gene interactions. Current 
study suggest that the genotype combination 
of two genes involved in metabolism of xeno-
biotics appears as a significant risk factor for 
the susceptibility to COPD.
Since genetic polymorphisms in xenobiot-
ic enzymes may play a role in individual sus-
ceptibility to oxidant-related lung disease, sev-
eral studies assessed the associations between 
COPD and candidate genes of enzymes in-
volved in the metabolism of mutagens and 
carcinogens originating in cigarette smoke. 
Epoxide derivatives of cigarette-smoke com-
ponents may be the cause of some of the lung 
damage characteristic of these diseases. In-
deed, Smith and Harrison (9) were the first to 
report a strong association between the innate 
slow EPHX1 activity (Tyr113His polymor-
phism of EPHX1 gene) and COPD. These 
findings were strengthened by further stud-
ies in Taiwanese (14) and Caucasian (15,35) 
populations. Nevertheless, since some authors 
failed to confirm these initial results (16-18), 
Brogger et al (36) performed a meta-analy-
sis of 16 studies on the associations between 
COPD and several candidate gene polymor-
phisms. This meta-analysis supported the role 
of EPHX1 in the etiology of COPD (36).
Although there has been some early evi-
dence that the GSTM1 null genotype might 
be related to severe bronchitis in heavy smok-
ers (37) and to the reduction in lung function 
and emphysema in smokers with broncho-
genic carcinoma (21,22), Hersh et al (35) did 
not find any significant association between 
the GSTM1 genotype and COPD. Similarly, 
Yim et al (17) did not find any associations be-
tween genetic polymorphisms in GSTM1 and 
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GSTT1 genes and the development of COPD 
in Koreans. In agreement with these findings, 
the results of our study could not provide any 
support for the possible relationship between 
the GSTM1 and GSTT1 gene polymorphisms 
and COPD in the Slovak population.
The most important finding of our study 
is that the combination of GSTM1 null gen-
otype and EPHX1 His113-His113 genotype 
significantly increased the risk of COPD. 
GSTM1 null genotype is related to the total 
lack of the GSTM1 enzyme activity, whereas 
the EPHX1 His 113 allele is conferred to be 
slow (11). Taken together, patients with the 
particular EPHX1 His113-His113/GSTM1 
null genotype combination might possess a de-
creased ability to detoxify carcinogenic com-
pounds contained in cigarette smoke and an 
impaired antioxidant protection, resulting 
in an increased risk for the development of 
COPD. Indeed, Cheng et al (14) reported in a 
Taiwanese population an increased odds ratio 
for COPD when two genotypes of at least one 
slow EPHX1 exon 3 allele and GSTM1 null 
were combined. To our knowledge, our study 
is the first to identify an increased risk for the 
development of COPD in the carriers of the 
combined GSTM1 null and slow EPHX1 gen-
otype in the Slovak population.
Several limitations might have influenced 
our results. First, the size of the studied pop-
ulation was moderate, thus affecting the po-
tential to detect and replicate the formerly re-
ported associations. Indeed, Brogger et al (36) 
have recently shown that the genetic associa-
tions tend to vary in small studies. The second 
potential source of bias in our study relates 
to the genotyping method that was original-
ly described by Smith and Harrison (9). In 
an association study on the relationship be-
tween EPHX1 gene polymorphism and em-
physema in a Japanese cohort, the frequency 
of His113, a possible emphysema susceptibili-
ty allele of the EPHX1 gene, was overestimat-
ed when DNA samples were genotyped in a 
conventional way (38). This pitfall for PCR-
based association studies on EPHX1 gene 
polymorphisms results from the interference 
of the nearby single nucleotide polymorphism 
(Lys119) with the primer hybridization, and 
therefore, the distribution of polymorphisms 
should be tested for Hardy-Weinberg equi-
librium (38). In our study, the distributions 
of EPHX1 gene polymorphisms were in Har-
dy-Weinberg equilibrium. Therefore, our re-
sults are likely unaffected by the potential bias 
resulting from the conventional way of ge-
notyping EPHX1 gene. Finally, a limitation 
common to most studies with similar design 
as ours is that they only try to find the associ-
ation in the genes previously known to be re-
lated to a given disease. A different approach, 
ie, the genome-wide scanning should be em-
ployed to find a novel genetic link to COPD.
In conclusion, in our study the combined 
EPHX1 His113-His113/GSTM1 null gen-
otype was associated with significantly in-
creased risk of COPD in Slovaks. Since simple 
association studies give only limited and of-
ten contradictory results, the real challenge is 
to understand the role of multiple genetic and 
environmental factors, as well as gene-gene and 
gene-environment interactions in the patho-
genesis of lung impairment in COPD.
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